Aizempa 10mg & 25mg Tablets
PDF Leaflet Revision Date: 19 February 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Adjunct treatment for type 2 diabetes and heart failure.
Dosage (summary)
Starting dose: 10 mg once daily; may increase to 25 mg if needed.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Increased risk of hypoglycaemia with insulin/sulphonylureas
- May enhance diuretic effects
Contraindications
- Hypersensitivity to empagliflozin
- Type 1 diabetes
- Ketoacidosis
- Moderate to severe renal impairment
Common side effects
- Hypoglycaemia
- Genital infections
- Urinary tract infections
Counselling Points
- Monitor for signs of ketoacidosis
- Stay hydrated
- Report any genital or urinary symptoms
Serious warnings
- Risk of diabetic ketoacidosis
- Volume depletion
- Fournier's gangrene
Important Disclaimer
The Aizempa 10mg & 25mg Tablets professional information leaflet below is the property of Austell Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
